The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00772538




Registration number
NCT00772538
Ethics application status
Date submitted
13/10/2008
Date registered
15/10/2008
Date last updated
18/08/2014

Titles & IDs
Public title
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
Scientific title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma
Secondary ID [1] 0 0
2008-001413-14
Secondary ID [2] 0 0
205.416
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - tiotropium 5mcg/day
Treatment: Drugs - placebo

Experimental: tiotropium 5mcg/day - patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution

Experimental: placebo - patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution


Treatment: Drugs: tiotropium 5mcg/day
Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo

Treatment: Drugs: placebo
Matching placebo

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. - Peak FEV1 0-3h response was defined as the difference between the maximum FEV1 measured within the first 3 hours post dosing after a treatment period of 24 weeks and the FEV1 baseline measurement (10 minutes before the first dose of trial medication). Mixed Model Repeated Measure (MMRM) results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [1] 0 0
Baseline and 24 weeks
Primary outcome [2] 0 0
Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. - The trough FEV1 is defined as the pre-dose FEV1 measured 10 minutes before the last administration of randomised treatment. Trough FEV1 response was defined as the difference between the trough FEV1 measured after a treatment period of 24 weeks and the FEV1 baseline measurement. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [2] 0 0
Baseline and 24 weeks
Primary outcome [3] 0 0
Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). - Severe asthma exacerbations were pre-defined as all asthma exacerbations that required treatment with systemic (including oral) corticosteroids for at least 3 days or (in case of ongoing and pre-existing systemic corticosteroid therapy) that required at least a doubling of the previous daily dose of systemic corticosteroids for at least 3 days.
Timepoint [3] 0 0
48 weeks
Secondary outcome [1] 0 0
Peak (Within 3 Hours Post-dosing) Forced Vital Capacity (FVC) Response at the End of the 24-week Treatment Period. - Peak FVC 0-3h response was defined as the difference between the maximum FVC measured within the first 3 hours post dosing after a treatment period of 24 weeks and the FVC baseline measurement (10 minutes before the first dose of trial medication). Mixed Model Repeated Measure (MMRM) results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [1] 0 0
Baseline and 24 weeks
Secondary outcome [2] 0 0
Trough FVC Response at the End of the 24-week Treatment Period. - The trough FVC is defined as the pre-dose FVC measured 10 minutes before the last administration of randomised treatment. Trough FVC response was defined as the difference between the trough FVC measured after a treatment period of 24 weeks and the FVC baseline measurement. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [2] 0 0
Baseline and 24 weeks
Secondary outcome [3] 0 0
FEV1 Area Under the Curve (AUC0-3h) Response at the End of the 24-week Treatment Period. - The AUC0-3h was calculated as area under the curve from zero to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. The trough value was assigned to zero time. Response was defined as change from baseline in FEV1 AUC0-3h after a treatment period of 24 weeks. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit baseline*visit.
Timepoint [3] 0 0
Baseline and 24 weeks
Secondary outcome [4] 0 0
FVC (AUC0-3h) Response at the End of the 24-week Treatment Period. - The AUC0-3h was calculated as area under the curve from zero to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. The trough value was assigned to zero time. Response was defined as change from baseline in FVC AUC0-3h after a treatment period of 24 weeks. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit baseline*visit.
Timepoint [4] 0 0
Baseline and 24 weeks
Secondary outcome [5] 0 0
Peak FEV1 0-3h Response at the End of the 48-week Treatment Period. - Peak FEV1 0-3h response was defined as the difference between the maximum FEV1 measured within the first 3 hours post dosing after a treatment period of 48 weeks and the FEV1 baseline measurement (10 minutes before the first dose of trial medication). Mixed Model Repeated Measure (MMRM) results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [5] 0 0
Baseline and 48 weeks
Secondary outcome [6] 0 0
Trough FEV1 Response at the End of the 48-week Treatment Period. - The trough FEV1 is defined as the pre-dose FEV1 measured 10 minutes before the last administration of randomised treatment. Trough FEV1 response was defined as the difference between the trough FEV1 measured after a treatment period of 48 weeks and the FEV1 baseline measurement. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [6] 0 0
Baseline and 48 weeks
Secondary outcome [7] 0 0
AUC0-3h FEV1 Response at the End of the 48-week Treatment Period. - The AUC0-3h was calculated as area under the curve from zero to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. The trough value was assigned to zero time. Response was defined as change from baseline in FEV1 AUC0-3h after a treatment period of 48 weeks. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit baseline*visit.
Timepoint [7] 0 0
Baseline and 48 weeks
Secondary outcome [8] 0 0
Peak FVC 0-3h Response at the End of the 48-week Treatment Period. - Peak FVC 0-3h response was defined as the difference between the maximum FVC measured within the first 3 hours post dosing after a treatment period of 48 weeks and the FVC baseline measurement (10 minutes before the first dose of trial medication). MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [8] 0 0
Baseline and 48 weeks
Secondary outcome [9] 0 0
Trough FVC Response at the End of the 48-week Treatment Period. - The trough FVC is defined as the pre-dose FVC measured 10 minutes before the last administration of randomised treatment. Trough FVC response was defined as the difference between the trough FVC measured after a treatment period of 48 weeks and the FVC baseline measurement. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [9] 0 0
Baseline and 48 weeks
Secondary outcome [10] 0 0
FVC AUC0-3h Response at the End of the 48-week Treatment Period. - The AUC0-3h was calculated as area under the curve from zero to 3 hours using the trapezoidal rule divided by the observation time (3 hours) to report in litres. The trough value was assigned to zero time. Response was defined as change from baseline in FVC AUC0-3h after a treatment period of 48 weeks. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit baseline*visit.
Timepoint [10] 0 0
Baseline and 48 weeks
Secondary outcome [11] 0 0
Mean Pre-dose Morning Peak Expiratory Flow (PEFa.m.) Response (Diary Data) of Last-7-days-before-week-24-visit . - Weekly means obtained during the last 7 days before week 24 visit were compared (measured by patients at home using the asthma monitor device). Response was defined as change from baseline. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [11] 0 0
Baseline and last 7 days before week 24 visit
Secondary outcome [12] 0 0
Mean Pre-dose Evening Peak Expiratory Flow (PEFp.m.) Response (Diary Data) of Last-7-days-before-week 24-visit. - Weekly means obtained during the last 7 days before week 24 visit were compared (measured by patients at home using the asthma monitor device). Response was defined as change from baseline. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [12] 0 0
Baseline and last 7 days before week 24 visit
Secondary outcome [13] 0 0
Mean Pre-dose FEV1 a.m. Response (Diary Data) of Last-7-days-before-week 24-visit. - Weekly means obtained during the last 7 days before week 24 visit were compared (measured by patients at home using the asthma monitor device). Response was defined as change from baseline. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [13] 0 0
Baseline and last 7 days before week 24 visit
Secondary outcome [14] 0 0
Mean Pre-dose FEV1-p.m.Response (Diary Data) of Last-7-days-before-week 24-visit. - Weekly means obtained during the last 7 days before week 24 visit were compared (measured by patients at home using the asthma monitor device). Response was defined as change from baseline. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [14] 0 0
Baseline and last 7 days before week 24 visit
Secondary outcome [15] 0 0
Mean PEF Variability Response (Absolute Difference Between Morning and Evening PEF Value Divided by Their Mean) of Last-7-days-before-week 24-visit. - Weekly means obtained during the last 7 days before week 24 visit were compared (measured by patients at home using the asthma monitor device). The PEF variability is the absolute difference between morning and evening PEF value divided by their mean, expressed as a percent. Response was defined as change from baseline. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [15] 0 0
Baseline and last 7 days before week 24 visit
Secondary outcome [16] 0 0
Time to First Severe Asthma Exacerbation During the 48-week Treatment. - Severe asthma exacerbations were pre-defined as all asthma exacerbations that required treatment with systemic (including oral) corticosteroids for at least 3 days or (in case of ongoing and pre-existing systemic corticosteroid therapy) that required at least a doubling of the previous daily dose of systemic corticosteroids for at least 3 days.
Timepoint [16] 0 0
48 weeks
Secondary outcome [17] 0 0
Number of Asthma Exacerbations Per Patient During the 48-week Treatment Period. - Asthma exacerbations (including severe, non-severe; symptomatic, asymptomatic) were pre-defined as an episode of progressive increase in 1 or more asthma symptoms (e.g. shortness of breath, cough, wheezing, chest tightness or some combination of these symptoms). Additionally, decrease of patients best PEF a.m. of 30 percent or more from the patients mean PEF a.m. for at least 2 consecutive days was considered to be an objective marker of asthma exacerbation.
Timepoint [17] 0 0
48 weeks
Secondary outcome [18] 0 0
Number of Severe Asthma Exacerbations Per Patient During the 48-week Treatment Period. - Severe asthma exacerbations were pre-defined as all asthma exacerbations that required treatment with systemic (including oral) corticosteroids for at least 3 days or (in case of ongoing and pre-existing systemic corticosteroid therapy) that required at least a doubling of the previous daily dose of systemic corticosteroids for at least 3 days.
Timepoint [18] 0 0
48 weeks
Secondary outcome [19] 0 0
Number of Patients With at Least One Asthma Exacerbation During the 48-week Treatment Period. - Asthma exacerbations (including severe, non-severe; symptomatic, asymptomatic) were pre-defined as an episode of progressive increase in 1 or more asthma symptoms (e.g. shortness of breath, cough, wheezing, chest tightness or some combination of these symptoms). Additionally, decrease of patients best PEF a.m. of 30 percent or more from the patients mean PEF a.m. for at least 2 consecutive days was considered to be an objective marker of asthma exacerbation.
Timepoint [19] 0 0
48 weeks
Secondary outcome [20] 0 0
Number of Patients With at Least One Severe Asthma Exacerbation During the 48-week Treatment Period. - Severe asthma exacerbations were pre-defined as all asthma exacerbations that required treatment with systemic (including oral) corticosteroids for at least 3 days or (in case of ongoing and pre-existing systemic corticosteroid therapy) that required at least a doubling of the previous daily dose of systemic corticosteroids for at least 3 days.
Timepoint [20] 0 0
48 weeks
Secondary outcome [21] 0 0
Time to First Hospitalisation for Asthma Exacerbation During the 48-week Treatment Period. - Asthma exacerbations (including severe, non-severe; symptomatic, asymptomatic) were pre-defined as an episode of progressive increase in 1 or more asthma symptoms (e.g. shortness of breath, cough, wheezing, chest tightness or some combination of these symptoms). Additionally, decrease of patients best PEF a.m. of 30 percent or more from the patients mean PEF a.m. for at least 2 consecutive days was considered to be an objective marker of asthma exacerbation.
Timepoint [21] 0 0
48 weeks
Secondary outcome [22] 0 0
Number of Hospitalisations for Asthma Exacerbations Per Patient During the 48-week Treatment Period.
Timepoint [22] 0 0
48 weeks
Secondary outcome [23] 0 0
Number of Patients With at Least One Hospitalisation for Asthma Exacerbation During the 48-week Treatment Period.
Timepoint [23] 0 0
48 weeks
Secondary outcome [24] 0 0
Quality of Life as Assessed by Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) at the End of the 24-week Treatment Period. - The AQLQ(S) total score was calculated as the mean of the responses to 32 questions for the domains Symptoms, Activity Limitations, Emotional Function and Environmental Stimuli and was analysed as an absolute value. The AQLQ(S) total score ranges from 1 (worst controlled) to 7 (best). MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [24] 0 0
24 weeks
Secondary outcome [25] 0 0
AQLQ(S) Total Score at the End of the 48-week Treatment Period. - The AQLQ(S) total score was calculated as the mean of the responses to 32 questions for the domains Symptoms, Activity Limitations, Emotional Function and Environmental Stimuli and was analysed as an absolute value. The AQLQ(S) total score ranges from 1 (worst controlled) to 7 (best). MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [25] 0 0
48 weeks
Secondary outcome [26] 0 0
Asthma Control as Assessed by Asthma Control Questionnaire (ACQ) at the End of the 24-week Treatment Period. - For the ACQ, the total score was calculated as the mean of the responses to 7 questions and was analysed as an absolute value. The score ranges from 0 (no impairment) to 6 (maximum impairment). MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [26] 0 0
24 weeks
Secondary outcome [27] 0 0
ACQ at the End of the 48-week Treatment Period. - For the ACQ, the total score was calculated as the mean of the responses to 7 questions and was analysed as an absolute value. The score ranges from 0 (no impairment) to 6 (maximum impairment). MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [27] 0 0
48 weeks
Secondary outcome [28] 0 0
Asthma Symptom Free Days Response During the Last-7-days-before-week-24-visit . - Weekly means obtained during the last 7 days before week 24 visit were compared (measured by patients at home using the asthma monitor device). The response is defined as the change of the weekly mean from the baseline weekly mean. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [28] 0 0
Baseline and last 7 days before week 24 visit
Secondary outcome [29] 0 0
Mean Pro Re Nata (as Needed, PRN) Rescue Medication Use Response During the Last-7-days-before-week-24-visit . - Weekly means obtained during the last 7 days before week 24 visit were compared. The response is defined as the change of the weekly mean from the baseline weekly mean. The use of PRN salbutamol (albuterol rescue medication) is determined by the number of puffs of rescue therapy used per day. MMRM results. Means are adjusted for treatment, centre, visit, baseline, treatment*visit and baseline*visit.
Timepoint [29] 0 0
Baseline and last 7 days before week 24 visit

Eligibility
Key inclusion criteria
Inclusion criteria:

1. All patients must sign and date an Informed Consent Form consistent with ICH-GCP
guidelines and local legislation prior to participation in the trial (i.e. prior to
any trial procedures, including any pre-trial washout of medications and medication
restrictions for pulmonary function test at Visit 1).

2. Male or female patients aged at least 18 years but not more than 75 years.

3. All patients must have at least a 5-year history of asthma at the time of enrolment
into the trial and the diagnosis of asthma must have been made before the patient´s
age of 40.

4. All patients must have a diagnosis of severe persistent asthma and must be symptomatic
despite treatment with high, stable doses of inhaled corticosteroids and a long-acting
beta adrenergic agent

5. All patients must have a history of one or more asthma exacerbation in the past year.

6. Patients must have evidence of treated, severe, persistent asthma in
postbronchodilatory pulmonary function tests.

7. Patients should be never-smokers or ex-smokers who stopped smoking at least one year
prior to enrolment and who have a smoking history of less than 10 pack years

8. Patients must be able to use the Respimat® inhaler correctly

9. Patients must be able to perform all trial related procedures including technically
acceptable pulmonary function tests and use of the electronic diary/peak flow meter.
Minimum age
18 Years
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Patients with a significant disease other than asthma. A significant disease is
defined as a disease which, in the opinion of the investigator, may (i) put the
patient at risk because of participation in the trial, or (ii) influence the results
of the trial, or (iii) cause concern regarding the patient´s ability to participate in
the trial.

2. Patients with clinically relevant abnormal screening haematology or blood chemistry.

3. Patients with a recent history (i.e. six months or less) of myocardial infarction,
hospitalisation for cardiac failure during the past year, any unstable or life
threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a
change in drug therapy within the past year, known active tuberculosis, malignancy for
which the patient has undergone resection, radiation therapy or chemotherapy within
the last five years (treated basal cell carcinoma allowed), lung diseases other than
asthma (e.g. COPD), significant alcohol or drug abuse within the past two years,
patients who have undergone thoracotomy with pulmonary resection. Patients with a
history of thoracotomy for other reasons should be evaluated as per exclusion
criterion No. 1.

4. Patients who are currently in a pulmonary rehabilitation program or have completed a
pulmonary rehabilitation program in the 6 weeks prior to the screening visit (Visit
1).

5. Patients using oral corticosteroid medication at stable doses exceeding 5 mg
prednisolone or prednisolone equivalent every day or 10 mg prednisolone or
prednisolone equivalent every second day.

6. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other
components of the tiotropium inhalation solution.

7. Pregnant or nursing women or women of childbearing potential not using a highly
effective method of birth control. Female patients will be considered to be of
childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal
ligation/salpingectomy, or post-menopausal for at least two years.

8. Patients who have taken an investigational drug within four weeks or six half-lives
(whichever is greater) prior to Visit 1.

9. Patients who have been treated with the long-acting anticholinergic tiotropium
(Spiriva®), beta-blocker medication, oral beta-adrenergics, other non-approved and
according to international guidelines not recommended ´experimental´ drugs for routine
asthma therapy (e.g. TNF-alpha blockers, methotrexate, cyclosporin) within four weeks
prior to the Screening Visit (Visit 1) or during the screening period.

10. Patients with any asthma exacerbation or respiratory tract infection in the four weeks
prior to the trial.

11. Patients who have previously been randomised in this trial or in the respective twin
trial (205.416 versus 205.417) or are currently participating in another trial.

12. Patients with a known narrow-angle glaucoma.

Note:

As with other anticholinergic drugs, tiotropium should be used with caution in patients
with prostatic hyperplasia or bladder neck obstruction.

As with all predominantly renally excreted drugs, patients with moderate to severe renal
impairment (known creatinine clearance of <= 50 mL/min) treated with tiotropium should be
monitored closely.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,WA
Recruitment hospital [1] 0 0
205.416.61001 Boehringer Ingelheim Investigational Site - Daw Park
Recruitment hospital [2] 0 0
205.416.61002 Boehringer Ingelheim Investigational Site - Woodville
Recruitment hospital [3] 0 0
205.416.61003 Boehringer Ingelheim Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
- Daw Park
Recruitment postcode(s) [2] 0 0
- Woodville
Recruitment postcode(s) [3] 0 0
- Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Virginia
Country [17] 0 0
Canada
State/province [17] 0 0
Ontario
Country [18] 0 0
Canada
State/province [18] 0 0
Quebec
Country [19] 0 0
Denmark
State/province [19] 0 0
Hvidovre
Country [20] 0 0
Denmark
State/province [20] 0 0
Odense C
Country [21] 0 0
Germany
State/province [21] 0 0
Berlin
Country [22] 0 0
Germany
State/province [22] 0 0
Gelnhausen
Country [23] 0 0
Germany
State/province [23] 0 0
Koblenz
Country [24] 0 0
Germany
State/province [24] 0 0
Oschersleben
Country [25] 0 0
Italy
State/province [25] 0 0
Pisa
Country [26] 0 0
Italy
State/province [26] 0 0
Sesto S. Giovanni (MI)
Country [27] 0 0
Japan
State/province [27] 0 0
Hachioji, Tokyo
Country [28] 0 0
Japan
State/province [28] 0 0
Inashiki-gun, Ibaraki
Country [29] 0 0
Japan
State/province [29] 0 0
Kamogawa, Chiba
Country [30] 0 0
Japan
State/province [30] 0 0
Maebashi, Gunma
Country [31] 0 0
Japan
State/province [31] 0 0
Minato-ku, Tokyo
Country [32] 0 0
Japan
State/province [32] 0 0
Naka-gun, Ibaraki
Country [33] 0 0
Japan
State/province [33] 0 0
Noda, Chiba
Country [34] 0 0
Japan
State/province [34] 0 0
Sapporo, Hokkaido
Country [35] 0 0
Japan
State/province [35] 0 0
Sendai, Miyagi
Country [36] 0 0
Japan
State/province [36] 0 0
shinagawa-ku, Tokyo
Country [37] 0 0
Japan
State/province [37] 0 0
Tsukuba, Ibaraki
Country [38] 0 0
Japan
State/province [38] 0 0
Yokohama, Kanagawa
Country [39] 0 0
Japan
State/province [39] 0 0
Yonezawa, Yamagata
Country [40] 0 0
Netherlands
State/province [40] 0 0
Breda
Country [41] 0 0
Netherlands
State/province [41] 0 0
Groningen
Country [42] 0 0
Netherlands
State/province [42] 0 0
Helmond
Country [43] 0 0
Netherlands
State/province [43] 0 0
Zutphen
Country [44] 0 0
Russian Federation
State/province [44] 0 0
Moscow
Country [45] 0 0
Russian Federation
State/province [45] 0 0
Reutov - Moscow region
Country [46] 0 0
Serbia
State/province [46] 0 0
Belgrade
Country [47] 0 0
Serbia
State/province [47] 0 0
Kragujevac
Country [48] 0 0
Serbia
State/province [48] 0 0
Zemun
Country [49] 0 0
South Africa
State/province [49] 0 0
Cape Town
Country [50] 0 0
South Africa
State/province [50] 0 0
Durban
Country [51] 0 0
South Africa
State/province [51] 0 0
Pretoria
Country [52] 0 0
Turkey
State/province [52] 0 0
Istanbul
Country [53] 0 0
Turkey
State/province [53] 0 0
Izmir
Country [54] 0 0
Ukraine
State/province [54] 0 0
Kharkov
Country [55] 0 0
Ukraine
State/province [55] 0 0
Kiev
Country [56] 0 0
Ukraine
State/province [56] 0 0
Vinnytsya
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Brighton
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Leicester
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Pfizer
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate
the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to
placebo. Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined
as add-on controller therapy on top of usual care in patients with severe persistent asthma.

The primary objective of each trial is to evaluate the long term efficacy of tiotropium over
placebo on top of usual care in patients with severe persistent asthma as determined by
pulmonary function testing, effects on asthma exacerbations, effects on quality of life, on
asthma control and health care resource utilisation. The secondary objective of each trial is
to compare the long term safety of tiotropium with placebo in this patient population.
Trial website
https://clinicaltrials.gov/show/NCT00772538
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications